we announced positive data in our Phase 2 trial in the very rare epilepsies, CDKL5 and Dup15Q. Then, on May 7, 2020, still locked down, we announced positive data in our Phase 2 trial in Fragile X. Looking to the future, we plan to deliver results from a large Phase 2 global trial in the rare epilepsies Dravet and Lenox Gastaut syndromes in the next few months, all on time. And finally, later in the year we expect to deliver results from our pivotal Phase 3 trial in Angelman syndrome.
Book seems largely like advertising so far for their various biotech ventures.
